Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference
KNSA Stock | USD 21.85 0.23 1.04% |
About 61% of Kiniksa Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Kiniksa Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Kiniksa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Kiniksa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Kiniksa |
LONDON, Nov. 12, 2024 -- Kiniksa Pharmaceuticals International, plc today announced that management will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 1200 p.m. Greenwich Mean Time . A live webcast of Kiniksas presentation will be accessible through the Investors section of the companys website at www.kiniksa.com. A replay of the event will also be available on Kiniksa
Read at finance.yahoo.com
Kiniksa Pharmaceuticals Fundamental Analysis
We analyze Kiniksa Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiniksa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiniksa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Kiniksa Pharmaceuticals is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Kiniksa Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kiniksa Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Kiniksa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiniksa Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Kiniksa Pharmaceuticals Related Equities
CHRS | Coherus BioSciences | 12.30 | ||||
LYRA | Lyra Therapeutics | 10.53 | ||||
ACLX | Arcellx | 8.69 | ||||
GOSS | Gossamer Bio | 4.29 | ||||
GPCR | Structure Therapeutics | 2.38 | ||||
KRON | Kronos Bio | 2.11 | ||||
KURA | Kura Oncology | 1.45 | ||||
COGT | Cogent Biosciences | 0.42 | ||||
DAWN | Day One | 0.65 | ||||
SPRO | Spero Therapeutics | 0.88 | ||||
BOLT | Bolt Biotherapeutics | 1.56 | ||||
PHAT | Phathom Pharmaceuticals | 1.80 | ||||
LRMR | Larimar Therapeutics | 2.05 | ||||
CGEM | Cullinan Oncology | 2.08 | ||||
NVCT | Nuvectis Pharma | 2.38 | ||||
NUVL | Nuvalent | 2.49 | ||||
REPL | Replimune | 3.76 | ||||
VTYX | Ventyx Biosciences | 5.97 |
Complementary Tools for Kiniksa Stock analysis
When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |